Haemonetics ( (HAE) ) has released its Q2 earnings. Here is a breakdown of the information Haemonetics presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Haemonetics Corporation is a global medical technology company specializing in innovative healthcare solutions, including hospital technologies, plasma collection systems, and blood component collection products.
In its latest earnings report, Haemonetics announced a 5% decrease in revenue for the second quarter of fiscal 2026, with total revenue reaching $327 million. Despite the decline, the company reported a rise in earnings per diluted share and adjusted earnings, reflecting improved profitability.
Key financial highlights include a 13.4% increase in adjusted earnings per diluted share to $1.27 and a 139.6% rise in free cash flow compared to the previous year. The company also experienced a significant improvement in gross margin, driven by pricing benefits and product mix adjustments. Additionally, Haemonetics repurchased $75 million in shares as part of its ongoing share repurchase program.
Looking ahead, Haemonetics has raised its fiscal 2026 guidance, projecting improved organic revenue growth and maintaining strong adjusted operating margins. The company remains focused on enhancing commercial execution and advancing growth initiatives to meet its long-term objectives.